ONO PHARMA USA, INC. is the US subsidiary of ONO PHARMACEUTICAL CO, LTD., an R&D-oriented pharmaceutical company founded in 1717 with headquarters in Osaka, Japan. For over 300 years, ONO has been committed to delivering novel medicines to patients with high unmet medical need. Our passion has led to first-in-class therapies including the world’s first chemically synthesized prostaglandins as well as nivolumab, the world’s first anti-PD-1 antibody. These drugs have changed the treatment paradigm and outlook for millions of people globally. Today, ONO has a growing pipeline of innovative therapeutics across four focus areas: Oncology, immunology, neurology, and specialty medicine. ONO is committed to Challenging the Unknown, relentlessly pursuing research that will bring safe and effective solutions to more patients around the world. Community Guidelines: https://www.ono-usa.com/sites/default/files/media_document/linkedIn_community_guidelines.pdf